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Abstract
Background: MicroRNAs (miRNAs) are small, noncoding RNAs (ribonucleic acids) that regulate translation. Several miRNAs
have been shown to be altered in whole cancer tissue compared to normal tissue when quantified by microarray. Based on
previous such evidence of differential expression, we chose to study the functional significance of miRNAs miR-30a and -191
alterations in human lung cancer.
Methodology/Principal Findings: The functional significance of miRNAs miR-30a and -191 was studied by creating stable
transfectants of the lung adenocarcinoma cell line A549 and the immortalized bronchial epithelial cell line BEAS-2B with
modest overexpression of miR-30a or -191 using a lentiviral system. When compared to the corresponding controls, both
cell lines overexpressing miR-30a or -191 do not demonstrate any significant changes in cell cycle distribution, cell
proliferation, adherent colony formation, soft agar colony formation, xenograft formation in a subcutaneous SCID mouse
model, and drug sensitivity to doxorubicin and cisplatin. There is a modest increase in cell migration in cell lines
overexpressing miR-30a compared to their controls.
Conclusions/Significance: Overexpression of miR-30a or -191 does not lead to an alteration in cell cycle, proliferation,
xenograft formation, and chemosensitivity of A549 and BEAS-2B cell lines. Using microarray data from whole tumors to
select specific miRNAs for functional study may be a suboptimal strategy.
Citation: Patnaik SK, Kannisto E, Yendamuri S (2010) Overexpression of MicroRNA miR-30a or miR-191 in A549 Lung Cancer or BEAS-2B Normal Lung Cell Lines
Does Not Alter Phenotype. PLoS ONE 5(2): e9219. doi:10.1371/journal.pone.0009219
Editor: Mikhail V. Blagosklonny, Roswell Park Cancer Institute, United States of America
Received December 11, 2009; Accepted January 24, 2010; Published February 15, 2010
Copyright:  2010 Patnaik et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work is supported by research grants from the Thoracic Surgery Foundation for Research and Education and the Cancer and Leukemia Group B; SY
is supported by a fellowship from the Buswell Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sai.yendamuri@roswellpark.org
Introduction
The significance of non-coding RNAs in the regulation of
cellular processes has come to be increasingly appreciated [1]. The
best studied non-coding RNAs are microRNAs (miRNAs), 18–25
nt-long small RNA that epigenetically regulate translation by
binding to a complementary ‘‘seed’’ sequence common to their
‘‘target’’ mRNA [2]. As this complementarity does not have to be
perfect, a single miRNA can regulate the expression of several
hundred genes simultaneously [3]. The explosion of microarray
technology has led to its application in miRNA genomics.
Therefore, before the function of a significant proportion of
miRNAs were known, miRNA profiling of several normal and
abnormal human tissues have been performed [4]. The distinct
difference between the data obtained between miRNA profiling
and mRNA profiling is in the magnitude of differential expression
seen in the comparison groups. Whereas several fold changes are
commonly seen in mRNA expression using these technologies, the
fold changes with miRNA experiments are more modest and are
typically in the 1- to 2-fold range. Therefore, experiments to study
the biological relevance of these modest fold changes are
important to evaluate the significance of these changes. Based
on previously published miRNA microarray data demonstrating
differences in expression in human cancers compared to the
corresponding normal tissue, two miRNAs were chosen in this
study for such biological experiments. These two miRNAs were
chosen because of consistent alterations in their expression
between normal and cancerous tissue of various organs, a bio-
informatic analysis of their predicted targets that suggested
important roles in cell proliferation and migration and little
published work on their functional roles in lung cancer.
MiR-30a is located on human chromosome 6q.13 and is
generated from an intronic transcriptional unit that produces three
miRNAs: miR-30a, -30c and -30e [5]. Two mature forms of the
gene exist – miR-30a-3p and miR-30a-5p. Several studies have
detected changes in miR-30a expression in human cancer. Calin et
al. demonstrated a down-regulation of miR-30a in chronic
lymphocytic leukemia (CLL) patients [6]. Similarly, miR-30a is
down-regulated in lung cancer [7], colon cancer [8], pancreatic
cancer [9], metastatic hepatocellular cancer (compared to
primary) [10] and in acute myeloid leukemia (AML) patients with
a t(11q23) translocation (compared to other AML patients) [11].
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9219MiR-30a is important for the development of the prefrontal cortex
via the regulation of brain-derived neurotrophic factor (BDNF)
[12] and in vertebrate hepatobiliary development [13]. Other
experimentally confirmed targets of miR-30a are adenylate kinase
(Ak1) and the GW182 protein (Tnrc6a), a component of the RNA
interference silencing complex [13].
MiR-191 is located on human chromosome 3p21.31 and is
generated from an intronic transcriptional unit that can produce
two miRNAs: miR-191 and -425 [5]. Only a single mature form of
miR-191 is known to exist. MiR-191 expression is up-regulated in
pancreatic [14], colon, lung and prostate [7] cancers. It is also up-
regulated in AML patients with abnormal karyotypes [11], and
down-regulated in patients with CLL [6]. MiR-191 expression is
also altered in lungs exposed to cigarette smoke [15]. No mRNA
targets of miR-191 have been experimentally verified.
In this study, we evaluate the phenotypic changes seen by
constitutive over-expression of miR-30a and -191, on a lung
adenocarcinoma cell line (A549) [16] and an immortalized
bronchial epithelial cell line (BEAS-2B) [17]. The A549 cell line
was chosen because of the existence of a large amount of
experimental data on its use in various assays. The BEAS-2B cell
line was chosen because it is the immortalized cell line closest to
normal bronchial epithelium. As the effects of overexpression of a
microRNA is context-specific, we compared the alterations in
phenotype of malignant and non-malignant cells.
Materials and Methods
Ethics Statement
All in vivo studies were approved by the Institutional Animal
Care and Use Committee of the Roswell Park Cancer Institute.
Cell Culture
A549 human bronchioloalveolar lung carcinoma and BEAS-2B
normal bronchial epithelial cell lines were obtained from ATCCH
(Manassas, VA). Cells were cultured, respectively, in Dulbecco’s
modified Eagle medium (+DMEM; InvitrogenH, Carlsbad, CA)
with 10% fetal bovine serum (PAA LaboratoriesH, Austria), and
LHC-9 medium (InvitrogenH)a t3 7 uCi n5 %C O 2. Stably-
transfected cells were cultured in the presence of 2 mg/ml
puromycin (RocheH, Indianapolis, IN).
Generation of Stably Transfected Cell Lines
Single-stranded DNA oligonucleotides with human pre-miR-30a
or -191 (miRBase accession IDs MI0000088 and MI0000465,
respectively) sequences and with restriction enzyme site overhangs
were obtained from Integrated DNA TechnologiesH (Coralville,
IA). Complementary sequences were annealed and the resulting
double-stranded DNA was ligated to Xho I/Not I-digested
pLemiR
TM vector (Open BiosystemsH, Huntsville, AL). A549 cells
were then infected with plasmids using the Trans-Lentiviral
TM
GIPZ packing system (Open Biosystems; Huntsville, AL) accord-
ing to the manufacturer’s protocol. Briefly, TLA-HEK293TTM
cells were transfected using Arrest-In
TM with 37.5 mg plasmid
DNA in serum free medium for 4 hours. Media was then replaced
with serum containing media for 36 hours. Media were collected,
centrifuged to remove cell debris and used to transfect A549 and
BEAS-2B cells. Forty eight hours after addition of virus,
transfected cells were selected for by adding 2 mg/ml puromycin
to growth medium.
Real Time RT-PCR (qPCR) for Quantification of Small RNAs
Total RNA (20 ng), isolated from cells using PureLink
TM
Micro-to-Midi total RNA isolation kit (Invitrogen) according to
the manufacturer’s protocol, was reverse transcribed using
TaqMan
TM reverse transcription kit (Applied BiosystemsH, Foster
City, CA) and RNA-specific primers provided with TaqMan
TM
microRNA assays (Applied BiosystemsH)i n1 5ml, with annealing
Figure 1. Quantitative RT-PCR for confirming over-expression
of miR-30a in A-30a and B-30a, and of miR-191 in A-191 and B-
191 cell lines, respectively. Expression is normalized to control cell
lines (A0 or B0).
doi:10.1371/journal.pone.0009219.g001
Table 1. Top ten pathways identified by pathway enrichment
analysis for miR-30a and -191.
Pathway
database Description of pathway P
miR -191
BioCarta CDK Regulation of DNA Replication 0.0001
GenMAPP Cell Cycle 0.0011
BioCarta Role of MEF2D in T-cell Apoptosis 0.0013
BioCarta Y branching of actin filaments 0.0015
BioCarta Phospholipase C d1 in phospholipid associated cell
signaling
0.0019
BioCarta Oxidative Stress Induced Gene Expression Via Nrf2 0.0024
BioCarta Nitric Oxide Signaling Pathway 0.0028
BioCarta Stathmin and breast cancer resistance to
antimicrotubule agents
0.0036
BioCarta Cell Cycle: G2/M Checkpoint 0.0041
BioCarta Control of Gene Expression by Vitamin D Receptor 0.0041
miR-30a
BioCarta Cyclins and Cell Cycle Regulation 0.0013
BioCarta Classical Complement Pathway 0.003
BioCarta ChREBP regulation by carbohydrates and cAMP 0.0094
BioCarta Adhesion and Diapedesis of Granulocytes 0.0107
BioCarta Complement Pathway 0.0107
BioCarta Neutrophil and Its Surface Molecules 0.0119
BioCarta Alternative Complement Pathway 0.0149
BioCarta Cyclin E Destruction Pathway 0.0183
BioCarta Cell Cycle: G1/S Check Point 0.0218
BioCarta Ghrelin: Regulation of Food Intake and Energy
Homeostasis
0.0218
BioCarta Monocyte and its Surface Molecules 0.0218
doi:10.1371/journal.pone.0009219.t001
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1.33 mL of the RT reaction was then used with 1 mL specific
primers for either RNU6B, miR-30a,o rmiR-191 (Applied
BiosystemsH, Foster City, CA) in triplicate wells for 44-cycle
PCR on a 7900HT thermocycler (Applied BiosystemsH). The
denaturation step at 95uC was for 15 s, and the annealing and
extension step at 60uC was for 1 min. SDS software (Applied
BiosystemsH, Foster City, CA) was used to determine cycle-
threshold (Ct) values of the fluorescence measured during PCR.
Prism 5.0b software (GraphPadH; La Jolla, CA) was used for
statistical analysis and graphing.
Pathway Enrichment Analysis
The publicly available miRgator software (http://genome.
ewha.ac.kr/miRGator/miRGator.html) was used to perform
pathway enrichment analysis. The specific miRNAs selected were
miR-191 and -30a-5p. The target selection algorithm chosen was
miRanda [3].
Cell Proliferation Assay
Cell proliferation assays were performed using the Cell Titer
96H kit (Promega; Madison, WI) which uses the conversion of
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium, inner salt) to formazan to measure
cell viability. Briefly, cells were plated on 96 well plates at 4,000
cells in 100 mL per well. Cells were harvested in quadruplicate at
various time points for 150 hours. To the harvested cells, 20 mLo f
assay reagent was added and viable cells were measured by
absorbance at 450 nm 1 hour later on a Multiskan Plus (MTX
Lab Systems; Vienna, VA) plate reader. Absorbance values were
normalized to media control.
Adherent Colony Formation
Cells in culture were trypsinized and plated in duplicate in 6-
well plates at 200 and cells per well for A549 and 500 cells per well
for BEAS-2B cell line derivatives respectively. Cells were allowed
to grow at 37uC, 5% CO2 with media changes every 3–4 days
until colonies were visible by eye. Media was aspirated and cells
were stained with 0.2% methylene blue in 40% methanol for
30 minutes. Cells were washed and plates were scanned using an
Epson Perfection V700 Photo scanner as a transparency.
Quantitation of colonies was done using ImageJ software
(Research Services Branch, National Institute of Mental Health,
Bethesda).
Soft Agar Colony Formation Assay
Base agar/media mix was added to 6-well plates (final
concentration of 0.7% agar, 1x +DMEM, 10% FBS, 2 mg/ml
Figure 2. Overexpression of miR-30a and -191 does not alter A549 and BEAS-2B cellular proliferation in-vitro and in-vivo. A,B. Cell
proliferation curves for cell lines A0, A-30a and A-191 (A) and B0, B-30a and B-191(B) demonstrating no change in cell proliferation. C. Methylene blue
stained cell culture plates demonstrating no difference in adherent colony formation in A-30a and A-191 compared to A0 and in B-30a and B-191
compared to B0. D. Xenograft formation in SCID mice by A549 is not altered by over-expression of miR-30a or -191.
doi:10.1371/journal.pone.0009219.g002
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suspensions were made to 100 cells/ml in media/agar mix (final
concentration of 0.35% agar, 1x +DMEM, 10% FBS, 2 mg/ml
puromycin). 1.5 ml of the cell suspension was plated on top of the
base agar in each well and allowed to polymerize. 2 ml complete
media was added on top of the agar once polymerized. The plates
were put in 37uC, 5% CO2, and overlay media was changed every
3–4 days. Cultures were grown until a few colonies were visible by
eye, 2 mg/ml Thiazolyl Blue Tetrazolium Bromide in PBS was
added to the cells and were returned to the incubator until colonies
were stained. Once colonies were stained blue, the stain was
removed from the wells and pictures were taken using Cannon
Powershot A590IS camera.
In Vitro Scratch Assay
To estimate differences in cell migration, an in-vitro scratch
assay was performed. Cross-hairs were drawn on the bottom of 6-
well plates for orientation for imaging. Cells were plated in
triplicate wells of at high density to reach 100% confluence 24
hours later. A scratch was then made directly next to the vertical
line drawn on the plate using moderate and consistent pressure
using a 10 mL tip and the plate lid as a straight edge. Scratches
were imaged immediately on an Axio Observer microscope (Zeiss;
Maple Grove, MN) at 5X magnification and orientation to the
cross-hairs noted. Cells were then returned to 37uC, 5% CO2 and
imaged at various time points until all scratches were closed.
Xenograft Formation Assay
All in vivo studies were approved by the Institutional Animal
Care and Use Committee of the Roswell Park Cancer Institute.
Control and over-expressing A549 cell lines (6.06105 cells) were
injected subcutaneously between the shoulder blades of 4–5 week
old SCID mice (5 mice in each cohort). Tumors were monitored
2–3 times per week by caliper measurements until the largest
tumor was 2 cm in longest direction, at which point all mice were
sacrificed. Tumors were dissected and weighed.
Cell Cycle Analysis
Cells grown to 70%–90% confluence were detached by
trypsinization, fixed in 70% ethanol at 4u C for 1–2 days, washed
with PBS, and incubated at a density of 122610
6 cells/ml with
0.3 mM 4,6-diamidino-2-phenylindole dihydrochloride (DAPI;
MP BiochemicalsH, Solon, OH) in PBS at room temperature in
the dark for 100 min. After washing once with PBS, DAPI
fluorescence from cells was assayed by flow cytometry using an
LSR II (BD BiosciencesH, San Jose, CA) instrument equipped with
a 408 nm violet laser diode and a 450/50 nm emission filter.
Drug Sensitivity Assay
After cells were grown to 50%–60% confluence in 96-well plates
(5 wells per cell-line), the medium was replaced with that
containing 1 mg/ml doxorubicin hydrochloride (Enzo Life Scien-
cesH, Farmingdale, NY) or cisplatin (CalbiochemH, San Diego,
CA). After 1.5–2 days of culture, viability of cells was measured as
described for the cell proliferation assay and compared to those
that were not exposed to the drugs.
Results
Creation of Stable Cell Lines with Over-Expression of miR-
30a and -191
Stable cell lines overexpressing miR-30a and -191 were
generated using a lentiviral system as described above. MiR-30a
was overexpressed ,2 fold and ,3 fold in both A549 (A-30a) and
BEAS-2B (B-30a) respectively compared to controls (A0 and B0
respectively). Compared to controls, miR-191 was overexpressed
,2 fold and ,7 fold in A549 (A-191) and BEAS-2B (B-191)
respectively (Figure 1). Overexpression was also confirmed by
visualization of RFP containing cells by microscopy.
Pathway Enrichment Analysis
Target prediction by the miRanda algorithm identified 731
targets for miR-30a-5p and 570 targets for miR-191. The top ten
pathways identified by the pathway enrichment analysis included
pathways influencing cell cycle, cell proliferation, drug resistance
and cell motility, among others (Table 1).
Over-Expression of miR-30a or -191 Does Not Alter
Measures of Proliferation Both In Vitro and In Vivo in A-
549 and BEAS-2B Cell Lines
Pathway enrichment analysis suggested that miR-30a and -191
influenced cell cycle and cell proliferation. To examine the effect
Figure 3. Analysis of migration and cell cycle with overexpres-
sion of miR-30a and -191. A. Cell migration of A-30a and B-30a is
increased compared to controls; no effect of overexpression of miR-191
is seen. B. Cell cycle analysis of stable transfectants demonstrating no
difference between cells over-expressing miR-30a and -191 compared
to controls.
doi:10.1371/journal.pone.0009219.g003
miR-30a and 191 in Lung Cancer
PLoS ONE | www.plosone.org 4 February 2010 | Volume 5 | Issue 2 | e9219of overexpression of miR-30a and -191 on A549 and BEAS-2B,
growth curves were plotted based on measurements of cell viability
at different time points over a 150-hour period. No difference in
growth curves were seen in A-30a and A-191 compared to A0 and
in B-30a and B-191 compared to B0 (Figure 2A, 2B). Cell
proliferation in different cell lines was also compared using
adherent colony formation. No difference was seen in either
number or size of adherent colonies in cell lines over-expressing
miR-30a or -191 compared to the corresponding control cell line
(Figure 2C).
A n c h o r a g ei n d e p e n d e n c ei so n eo ft h eh a l l m a r k so ft r a n s f o r -
mation. We sought to determine the effect of overexpression of
miR-30a or -191 on anchorage independent growth of A549 and
BEAS-2B cells using the soft agar colony assay as described
above. All lines formed very few colonies that were visible by
microscopy with only 2–3 colonies visible by naked eye. No
differences were seen after staining or by microscopy (data not
shown).
Xenograft formation is thought to represent a biologically
relevant measure of tumor aggressiveness. We assessed the effect of
overexpression of miR-30a or -191 on xenograft formation in
SCID mice by A549 cells. When compared to the control cell line
(A0), A-30a and A-191 do not form larger xenografts (Figure 2D).
The increase of tumor volume over time is also no different in
these cell lines compared to control (data not shown). As the
BEAS-2B cell line is non-tumorigenic, we did not assess xenograft
formation using B0, B-30a or B-191.
The Effect of Over-Expression of miR-30a or -191 on Cell
Migration and Cell Cycle Distribution of A-549 and BEAS-
2B Cell Lines
Increased cell migration is an important mechanism that is
thought to increase metastatic potential of cancer cells. This may
be independent of cell proliferation rates. Therefore, we studied
the effect of miR-30a or -191 on cell migration of A549 and BEAS-
2B cell lines using the scratch assay as described above. There is a
modest increase in the migration of A-30a and B-30a compared to
A0 and B0 respectively. There was no significant difference in the
migration distance between cell lines overexpressing miR-191
when compared to the corresponding control cell lines (Figure 3A).
An examination of the predicted targets of miR-30a and -191
and the cellular processes influenced by them shows a statistically
significant enrichment of pathways involving the cell cycle.
Therefore, we studied the effect of overexpression of miR-30a or
-191 on cell cycle distribution. Flow cytometry after staining with
DAPI was used to perform cell cycle analysis of all cell lines.
Compared to the controls, cell lines over-expressing miR-30a or
-191 do not show significant changes in the cell cycle distribution
(Figure 3B).
Over-Expression of miR-30a or -191 Does Not Alter
Chemosensitivity to Doxorubicin or Cisplatin
Doxorubicin and cisplatin are commonly used chemotherapeu-
tic agents. A549 is moderately sensitive to cisplatin and
Figure 4. Chemosensitivity is not altered by over-expression of miR-30a or -191. Sensitivity of A549 cells (A,B) and BEAS-2B cells (C,D) to
doxorubicin and cisplatin. Grey indicates control cells.
doi:10.1371/journal.pone.0009219.g004
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both increased and decreased sensitivity to these drugs. Overex-
pression of miR-30a or -191 does not alter the chemosensitivity of
A549 and BEAS-2B to either drug (Figure 4).
Discussion
MiRNA changes are commonly seen in cancerous tissue
compared to their normal counterparts. The magnitude of these
changes are modest and their functional significance in unknown.
One of the difficulties in the study of miRNAs are that one
miRNA has several hundred predicted targets and these bio-
informatic predictions are not very accurate. Also, the role of
miRNAs in a cell depends on the genetic constitution and the
transcriptome of a cell at any given time and this complexity is not
captured simply by their forced over-expression. However,
phenotypic alterations secondary to forced over-expression can
provide clues to understand their contribution to the malignant
phenotype. In this study, we generated stable transfectants that
constitutively over-express miR-30a or -191 and do not demon-
strate significant changes in phenotype in the various assays that
were performed. A number of possible explanations can explain
this lack of alteration of phenotype. First, it is possible that the level
of expression of the miRNAs achieved is not enough to create a
difference. Even though the fold changes seen by microarray
experiments is typically modest, such experiments may underes-
timate actual changes in malignant epithelial cells due to the
dilution of changes in malignant epithelial cells by stromal cells
that constitute a significant proportion of pathological specimens.
Also, the magnitude of changes seen by microarrays is often
smaller than the corresponding changes seen by RT-PCR.
Therefore, the actual changes in malignant cells may be more
than that achieved in our model system. Conversely, it is possible
that the changes seen in miRNA microarrays spuriously
overestimate changes. For example, in a study by Peltier
et al[18] that carefully evaluated several candidate miRNAs for
stability of expression across five types of cancer and normal tissues
by RT-PCR, miR-191 was so stably expressed that it was proposed
as a gene to be used for normalization. This argues against a role
for miR-191 in carcinogenesis. Therefore, selecting miRNAs based
on microarray data may not be a good strategy. Third, all
miRNAs may not be able to result in phenotypic changes on their
own; their effect may be context specific and may need to be
coupled with alterations of expression of either other miRNAs or
mRNAs to alter phenotype.
In summary, we conclude that over-expression of miR-30a or -
191 does not lead to an alteration in cell cycle, proliferation,
xenograft formation and chemosensitivity of A549 and BEAS-2B
cell lines. Using microarray data from whole tumors to select
specific miRNAs for functional study may be a sub-optimal
strategy. It is important to confirm the functional significance of
changes seen in miRNA expression data in specific tumor types to
define the biological roles of specific miRNAs.
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